Choose your language

30th ECNP Congress 2017

2-5 September 2017, Paris, France

The annual ECNP Congress is Europe’s premier scientific meeting for disease-oriented brain research, annually attracting between 4,000 and 6,000 neuroscientists, psychiatrists, neurologists and psychologists from around the world for the science and treatment of disorders of the brain. Click here for more information.

Tue 5 Sept

S.31: TNM symposium – Common mechanisms and therapeutic avenues for Down syndrome and other genetic developmental disorders


T21RS International Conference 2017

Chicago, 7-11 June 2017

After the succesful first edition of the bi-annual T21RS International Conference in 2015 in Paris (France), the second T21RS International Conference was held from June 7-11 in the beautiful city of Chicago (USA). 

The international Down syndrome research community gathered for the T21RS International Conference 2017 at the Feinberg School of Medicine of Northwestern University in the heart of the city of Chicago. Presentations and posters franged from basic to clinical research, with one entire day dedicated to Down syndrome and Alzheimer’s disease, reflecting new research opportunities to serve both the trisomic and euploid populations. The T21RS Science & Society Symposium included family-oriented presentations on choosing to participate or not in clinical trials and establishing structures to integrate medical care and social support for the community.

Click on the right (green download button) to download the abstract book (members-only, after log-in).


DYRK1A, related kinases & human disease

Saint-Malo, France,   March 28 - April 1st 2017


12ème Journée mondiale de la trisomie 2

Grenoble, France, March 16 - March 18 2017


29th ECNP Congress VIENNA

17 - 21 September 2016

The European College of Neuropsychopharmacology (ECNP) is a pan-European scientific association founded in 1987 to encourage innovative research across the neurosciences and to translate new knowledge on fundamental disease mechanisms into new medicines and clinical applications.

  • Symposium Saturday 17 September, 16:50 - 18:30 Room: Hall E1

Photo taken after the symposium with the four speakers of the session.

Alzheimer-type dementia in people with Down syndrome

  • Targeted Network Meeting 21 September 2016, 08:00-15:00 Room: Hall M2

Down Syndrome and Other Genetic Developmental Disorders Network


Down Syndrome Medical Interest Group-USA (DSMIG-USA) 2016 Annual Symposium

July 22, 2016

Orlando, Florida

Keystone Symposia meeting

Biology of Down Syndrome: Impacts Across the Biomedical Spectrum

Date: January 24–27, 2016
Location: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, New Mexico, USA
Scientific Organizers: Victor Tybulewicz, Elizabeth Fisher, Thomas Blumenthal, Jeanne Lawrence


SFN Neuroscience meeting, Chicago: Minisymposia

New Perspectives for the Rescue of Cognitive Disability in Down Syndrome

Chair: Renata Bartesaghi, University of Bologna
Co-Chair: Diana Bianchi, MD, Tufts University School of Medicine
Date & Time: Monday, October 19, 2015 1:30pm - 4pm

Down syndrome is a relatively high-incidence genetic condition caused by the triplication of human chromosome 21. No therapies currently exist for the rescue of cognitive impairment in Down syndrome. This minisymposium will present exciting findings showing that it is possible to restore brain development and cognitive performance in mouse models of Down syndrome with therapies usable in humans. This knowledge provides a breakthrough for the cure and prevention of intellectual disability in Down syndrome.



French Neuroscience Society - Special Symposium

SP03 Correction of synaptopathies in Down syndrome

Date: May 21, 2015
Chairs: X. Liogier (Basel) and M-C. Potier


Modèles cellulaires pour étudier la régulation des réseaux génétiques dans la trisomie 21 pour la recherche de cibles thérapeutiques / In vitro models to study dysregulation of genetic regulatory circuits in Down syndrome. A quest for therapeutic targets

  • P.A. Caviedes (Santiago)


La trisomie 21 et les interactions génétiques complexes : les voies alternatives pour améliorer les déficits cognitifs / Tackling the complexity of candidate gene interactions in DS mouse models, insights for new therapeutic intervention

  • Y. Herault (Illkirch)


Synaptopathies préfrontales liées à la surexpression du gène DYRK1A / Prefrontal synaptopathies linked to the Down syndrome candidate gene DYRK1A overexpression

  • A. Thomazeau (Cambridge)


Les traitements de la trisomie 21 ciblant DYRK1A / Corrective strategies targeting DYRK1A

  • J.-M. Delabar (Paris)


Développement clinique du RG1662 pour le traitement des déficits intellectuels dans la trisomie 21 / Development of RG1662 for the treatment of intellectual disability associated with Down syndrome

  • X. Liogier (Basel)